Skip to main content
Top

26-06-2015 | Esophageal cancer | Article

Management of Locally Advanced Adenocarcinoma of the Esophagus and Gastroesophageal Junction: Finally a Consensus

Journal: Current Treatment Options in Oncology

Authors: Lawrence Kleinberg, MD, Malcolm Brock, MD, Michael Gibson, MD, PhD

Publisher: Springer US

Abstract

Adenocarcinoma of the esophagus is increasing in incidence in Western nations leading to increased interest in and opportunity to study optimal management. Randomized trials have now robustly demonstrated the preoperative therapy with chemoradiotherapy and chemotherapy alone improves survival outcome for the bulk of curable patients, those with locally advanced T1N1M0 and T2-3 N0-1 M0 disease. Evidence suggests but does not confirm that radiation-containing regimens are more beneficial. Clinical staging is designed to exclude patients with T1N0M0 disease who may be treated with surgery alone and those with metastatic disease who may not benefit from intensive local therapy. The approach to clinical staging includes endoscopy with ultrasound and fine needle aspirate to assess local and regional disease, supplemented by CT and PET scanning primarily to exclude metastatic disease. Minimally invasive approaches to esophagectomy may be used with the goal of reducing complications, but there is no evidence that mortality or ultimate outcome is improved.
Literature
1.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.PubMedCrossRef
2.
DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252–71.PubMedCrossRef
3.
Hur C, Miller M, Kong CY, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013;119(6): 1149–58.
4.
Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC cancer staging manual: esophagus and esophagogastric junction. Ann Surg Oncol. 2010;17(7):1721–4.PubMedCrossRef
5.
Rice TW, Rusch VW, Apperson-Hansen C, et al. Worldwide esophageal cancer collaboration. Dis Esophagus. 2009;22(1):1–8.PubMedCrossRef
6.•
Rice TW, Rusch VW, Ishwaran H, Blackstone EH, Worldwide Esophageal Cancer Collaboration. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the american joint committee on cancer/international union against cancer cancer staging manuals. Cancer. 2010;116(16):3763–73. Describes the creation of the updated staging system for esophageal neoplasms using a large outcome data set.PubMedCrossRef
7.
Strong VE, D’Amico TA, Kleinberg L, Ajani J. Impact of the 7th edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers. J Natl Compr Canc Netw. 2013;11(1):60–6.PubMed
8.
Gertler R, Stein HJ, Langer R, et al. Long-term outcome of 2920 patients with cancers of the esophagus and esophagogastric junction: evaluation of the new union internationale contre le cancer/american joint cancer committee staging system. Ann Surg. 2011;253(4):689–98.PubMedCrossRef
9.
Cordin J, Lehmann K, Schneider PM. Clinical staging of adenocarcinoma of the esophagogastric junction. Recent Results Cancer Res. 2010;182:73–83.PubMedCrossRef
10.
Puli SR, Reddy JB, Bechtold ML, Antillon D, Ibdah JA, Antillon MR. Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and systematic review. World J Gastroenterol. 2008;14(10):1479–90.PubMedCentralPubMedCrossRef
11.
van Vliet EP, Heijenbrok-Kal MH, Hunink MG, Kuipers EJ, Siersema PD. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer. 2008;98(3):547–57.PubMedCentralPubMedCrossRef
12.
Polkowski M. Endosonographic staging of upper intestinal malignancy. Best Pract Res Clin Gastroenterol. 2009;23(5):649–61.PubMedCrossRef
13.
Vazquez-Sequeiros E, Norton ID, Clain JE, et al. Impact of EUS-guided fine-needle aspiration on lymph node staging in patients with esophageal carcinoma. Gastrointest Endosc. 2001;53(7):751–7.PubMedCrossRef
14.
Vazquez-Sequeiros E, Levy MJ, Clain JE, et al. Routine vs. selective EUS-guided FNA approach for preoperative nodal staging of esophageal carcinoma. Gastrointest Endosc. 2006;63(2):204–11.PubMedCrossRef
15.
Peng HQ, Greenwald BD, Tavora FR, et al. Evaluation of performance of EUS-FNA in preoperative lymph node staging of cancers of esophagus, lung, and pancreas. Diagn Cytopathol. 2008;36(5):290–6.PubMedCrossRef
16.
Crabtree TD, Kosinski AS, Puri V, et al. Evaluation of the reliability of clinical staging of T2 N0 esophageal cancer: a review of the society of thoracic surgeons database. Ann Thorac Surg. 2013;96(2):382–90.PubMedCentralPubMedCrossRef
17.
Speicher PJ, Ganapathi AM, Englum BR, et al. Induction therapy does not improve survival for clinical stage T2N0 esophageal cancer. J Thorac Oncol. 2014;9(8):1195–201.PubMedCrossRef
18.
Purandare NC, Pramesh CS, Karimundackal G, et al. Incremental value of 18F-FDG PET/CT in therapeutic decision-making of potentially curable esophageal adenocarcinoma. Nucl Med Commun. 2014;35(8):864–9.PubMed
19.
Wong R, Walker-Dilks C, Raifu A. Evidence-based guideline recommendations on the use of positron emission tomography imaging in oesophageal cancer. Clin Oncol (R Coll Radiol). 2012;24(2):86–104.CrossRef
20.••
van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84. A well poweredrandomized trial confirming, using a well tolerated regimen, that neoadjuvant chemoradiation improves survival outome.PubMedCrossRef
21.
Hulshof MC, Oppedijk V, van der Gaast A. Reply to E. C. smyth et al. J Clin Oncol. 2014;32(27):3081–3082.
22.••
Oppedijk V, van der Gaast A, van Lanschot JJ, et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol. 2014;32(5):385–91. Patterns of failure outcome data from a well powered randomized trial confirming that neoadjuvant chemoradiation reduces both local and distant failure.PubMedCrossRef
23.•
Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335(7):462–7. A randomized trial, underpowered as it closed for an early stopping rule, that suggested a benefit to preoperative chemoradiation.PubMedCrossRef
24.
Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19(2):305–13.PubMed
25.
Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26(7):1086–92.PubMedCrossRef
26.
Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005;6(9):659–68.PubMedCrossRef
27.•
Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681–92. A metanalysis of randomized data emphasizing that both eoadjuvant chemoradiation and chemotherapy alone can improve survival outcome, but that radiation containing regimens apepar superior.PubMedCrossRef
28.
Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data. Eur J Cancer. 2013;49(15):3149–58.PubMedCrossRef
29.
Hamilton E, Vohra RS, Griffiths EA. What is the best neoadjuvant regimen prior to oesophagectomy: chemotherapy or chemoradiotherapy? Int J Surg. 2014;12(3):196–9.PubMedCrossRef
30.
Bass GA, Furlong H, O’Sullivan KE, Hennessy TP, Walsh TN. Chemoradiotherapy, with adjuvant surgery for local control, confers a durable survival advantage in adenocarcinoma and squamous cell carcinoma of the oesophagus. Eur J Cancer. 2014;50(6):1065–75.PubMedCrossRef
31.
Gaast AV, Van Hagen P, Hulshof D. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: results from a randomized phase III study. J Clin Oncol. 2010;28(15a):4004.
32.
van Meerten E, Muller K, Tilanus HW, et al. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. Br J Cancer. 2006;94(10):1389–94.PubMedCentralPubMedCrossRef
33.
Kim DW, Blanke CD, Wu H, et al. Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys. 2007;67(2):397–404.PubMedCrossRef
34.
Ilson DH, Minsky BD, Ku GY, et al. Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. Cancer. 2012;118(11):2820–7.PubMedCrossRef
35.
Kleinberg L, Catalano P, Forastiere A. Long-term survival outcome of E1201: An eastern cooperative oncology group (ECOG) randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/radiotherapy (RT) or irinotecan/cisplatin/RT in endoscopy with ultrasound (EUS) staged esophageal adenocarcinoma. J Clin Oncol. 2012;30:suppl 4, abstr 69.
36.
Kleinberg LR, Eapen S, Hamilton S, Keller S, Forastiere AA, Anne P,  Benson AB. E1201: An eastern cooperative oncology group (ECOG) randomized phase II trial to measure response rate and toxicity of preoperative combined modality paclitaxel/cisplatin/RT or irinotecan/cisplatin/RT in adenocarcinoma of the esophagus. Proc ASTRO. 2006. doi:10.​1016/​j.​ijrobp.​2006.​07.​174.
37.
Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998;339(27):1979–84.PubMedCrossRef
38.
Kelsen DP, Winter KA, Gunderson LL, et al. Long-term results of RTOG trial 8911 (USA intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007;25(24):3719–25.PubMedCrossRef
39.
Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27(30):5062–7.PubMedCrossRef
40.
Medical Research Council Oesophageal Cancer Working Party. Surgical resection with or without preoperative chemotherapy inoesophageal cancer: a randomised controlled trial. Lancet. 2002;359(9319):1727–33.CrossRef
41.
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.PubMedCrossRef
42.
Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–21.PubMedCrossRef
43.
Griffin JM, Reed CE, Denlinger CE. Utility of restaging endoscopic ultrasound after neoadjuvant therapy for esophageal cancer. Ann Thorac Surg. 2012;93(6):1855–9. discussion 1860.PubMedCrossRef
44.
Jost C, Binek J, Schuller JC, et al. Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a prospective multicenter phase ll study by the swiss group for clinical cancer research (SAKK 75/02). Gastrointest Endosc. 2010;71(7):1114–21.PubMedCrossRef
45.
Heinzow HS, Seifert H, Tsepetonidis S, et al. Endoscopic ultrasound in staging esophageal cancer after neoadjuvant chemotherapy—results of a multicenter cohort analysis. J Gastrointest Surg. 2013;17(6):1050–7.PubMedCrossRef
46.
Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA, Eloubeidi MA. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg. 2005;129(6):1232–41.PubMedCrossRef
47.
Schollaert P, Crott R, Bertrand C, D’Hondt L, Borght TV, Krug B. A systematic review of the predictive value of (18)FDG-PET in esophageal and esophagogastric junction cancer after neoadjuvant chemoradiation on the survival outcome stratification. J Gastrointest Surg. 2014;18(5):894–905.PubMedCrossRef
48.
Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8(9):797–805.PubMedCrossRef
49.
zum Buschenfelde CM, Herrmann K, Schuster T, et al. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. J Nucl Med. 2011;52(8):1189–96.CrossRef
50.
Scheer RV, Fakiris AJ, Johnstone PA. Quantifying the benefit of a pathologic complete response after neoadjuvant chemoradiotherapy in the treatment of esophageal cancer. Int J Radiat Oncol Biol Phys. 2011;80(4):996–1001.PubMedCrossRef
51.
Herskovic A, Martz K, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326(24):1593–8.PubMedCrossRef
52.
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.PubMedCrossRef
53.
Esophageal and esophagogastric junction cancers. NCCN Clinical Practice Guidelines in Oncology. 2015;Version 1.
54.
Stahl M, Mariette C, Haustermans K, Cervantes A, Arnold D. ESMO guidelines working group. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi51–6.PubMedCrossRef
55.•
Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27(6):851–6. A randomized trial, underpowered as it closed for poor accrual, which suggested that radiotherapy improves both survival and local control when added to preoperative chemotherapy.PubMedCrossRef
56.
Kumagai K, Rouvelas I, Tsai JA, et al. Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers. Br J Surg. 2014;101(4):321–38.PubMedCrossRef
57.
Orringer MB, Marshall B, Chang AC, Lee J, Pickens A, Lau CL. Two thousand transhiatal esophagectomies: changing trends, lessons learned. Ann Surg. 2007;246(3):363–72. discussion 372–4.PubMedCentralPubMedCrossRef
58.
Omloo JM, Lagarde SM, Hulscher JB, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg. 2007;246(6):992–1000. discussion 1000–1.PubMedCrossRef
59.
Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347(21):1662–9.PubMedCrossRef
60.
Nishimaki T, Suzuki T, Suzuki S, Kuwabara S, Hatakeyama K. Outcomes of extended radical esophagectomy for thoracic esophageal cancer. J Am Coll Surg. 1998;186(3):306–12.PubMedCrossRef
61.
Bhansali MS, Fujita H, Kakegawa T, et al. Pattern of recurrence after extended radical esophagectomy with three-field lymph node dissection for squamous cell carcinoma in the thoracic esophagus. World J Surg. 1997;21(3):275–81.PubMedCrossRef
62.
Nishihira T, Hirayama K, Mori S. A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus. Am J Surg. 1998;175(1):47–51.PubMedCrossRef
63.
Wei B, D’Amico TA. Thoracoscopic versus robotic approaches: advantages and disadvantages. Thorac Surg Clin. 2014;24(2):177–88. vi.PubMedCrossRef
64.
Dantoc M, Cox MR, Eslick GD. Evidence to support the use of minimally invasive esophagectomy for esophageal cancer: a meta-analysis. Arch Surg. 2012;147(8):768–76.PubMedCrossRef
65.
Dantoc MM, Cox MR, Eslick GD. Does minimally invasive esophagectomy (MIE) provide for comparable oncologic outcomes to open techniques? A systematic review. J Gastrointest Surg. 2012;16(3):486–94.PubMedCrossRef
66.
Luketich JD, Pennathur A, Awais O, et al. Outcomes after minimally invasive esophagectomy: review of over 1000 patients. Ann Surg. 2012;256(1):95–103.PubMedCentralPubMedCrossRef
67.•
Biere SS, van Berge Henegouwen MI, Maas KW, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet. 2012;379(9829):1887–92. A randomized comparison suggesting that inimall invasive esophagectomy can achieve an appropriate resection with improved morbidity.PubMedCrossRef
68.
Cuesta MA, Biere SS, Henegouwen MI, van der Peet DL. Randomised trial, minimally invasive oesophagectomy versus open oesophagectomy for patients with resectable oesophageal cancer. J Thorac Dis. 2012;4(5):462–4.PubMedCentralPubMed
69.•
Mariette C, Meunier B, Pezet D. Hybrid minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicenter, open-label, randomized phase III controlled trial, the MIRO trial. J Clin Oncol. 2015;33 suppl 3:5. A randomized comparison suggesting that minimal invasive esophagectomy can achieve an appropriate resection with improved morbidity.
70.
Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.PubMedCrossRef
71.
Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30(19):2327–33.PubMedCrossRef
72.
Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85–01). radiation therapy oncology group. JAMA. 1999;281(17):1623–7.PubMedCrossRef
73.
Suntharalingam M, Winter K, Ilson D. The initial report of RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for patients with esophageal cancer treated without surgery. J Clin Oncol. 2014;32 suppl 3:6.